Sixteen patients with HNF1A diabetes ( 8 women ; mean age 39 years [ range 23-67 years ] ; BMI 24.9 0.5 kg/m ( 2 ) [ mean SEM ] ; fasting plasma glucose [ FPG ] 9.9 0.9 mmol/L ; HbA1c 6.4 0.2 % [ 47 3 mmol/mol ] ) received 6 weeks of treatment with a GLP-1RA ( liraglutide ) and placebo ( tablets ) , as well as a sulfonylurea ( glimepiride ) and placebo ( injections ) , in randomized order , in a double-blind , crossover trial .